Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSU-68 (orantinib) plus TACE in unresectable hepatocellular carcinoma
jRCT2080221317Phase 3
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Orantinib (TSU-68) + TACE with Placebo + TACE (2 arms).
02
Drugs
orantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080221317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221317.